Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

896
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
896
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

549
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
549
Inhaled Medications01:23

Inhaled Medications

840
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
840
Pulmonary Ventilation: Inhalation01:24

Pulmonary Ventilation: Inhalation

8.5K
Pulmonary ventilation is a vital process that ensures the exchange of oxygen and carbon dioxide in the lungs. It refers to the movement of air into and out of the lungs, enabling the body to obtain oxygen and remove waste carbon dioxide. In this article, we will explore the intricacies of pulmonary ventilation, including its underlying principles, mechanisms, and the interplay of pressures within the respiratory system.
Boyle's law becomes particularly pertinent when examining respiratory...
8.5K
Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

1.2K
Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
1.2K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.6K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dupilumab outcomes in pediatric asthma by early eosinophil status: post hoc analysis of VOYAGE/EXCURSION.

The Journal of allergy and clinical immunology·2026
Same author

Joint modelling of wheeze and lung function from childhood to early adulthood: four population-based birth cohorts.

EClinicalMedicine·2026
Same author

Global Initiative for Asthma Updates for Diagnosing Asthma in Adults.

JAMA network open·2026
Same author

Expectations and attitudes in primary care towards home-based testing for diagnosing asthma: a mixed methods study.

BJGP open·2026
Same author

Protocol for an open labelled observational study in children & adolescents with severe asthma with an eosinophilic phenotype treated with mepolizumab (CASAM).

PloS one·2025
Same author

Re-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease.

PharmacoEconomics·2025

Related Experiment Video

Updated: Feb 14, 2026

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis
07:56

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis

Published on: June 10, 2022

3.3K

Inhaled mannitol for cystic fibrosis.

Sarah J Nevitt1, Judith Thornton, Clare S Murray

  • 1Department of Biostatistics, University of Liverpool, Block F, Waterhouse Building, 1-5 Brownlow Hill, Liverpool, UK, L69 3GL.

The Cochrane Database of Systematic Reviews
|February 10, 2018
PubMed
Summary

Inhaled dry powder mannitol improves lung function in cystic fibrosis patients compared to control, but evidence on quality of life is limited. Further research is needed to confirm long-term benefits and compare mannitol with other mucolytic therapies.

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

1.2K
Expression and Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein in Saccharomyces cerevisiae
14:56

Expression and Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein in Saccharomyces cerevisiae

Published on: March 10, 2012

19.1K

Related Experiment Videos

Last Updated: Feb 14, 2026

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis
07:56

Rectal Organoid Morphology Analysis ROMA: A Diagnostic Assay in Cystic Fibrosis

Published on: June 10, 2022

3.3K
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

1.2K
Expression and Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein in Saccharomyces cerevisiae
14:56

Expression and Purification of the Cystic Fibrosis Transmembrane Conductance Regulator Protein in Saccharomyces cerevisiae

Published on: March 10, 2012

19.1K

Area of Science:

  • Pulmonary Medicine
  • Pharmacology
  • Genetics

Background:

  • Cystic fibrosis (CF) management involves airway secretion clearance.
  • Mannitol is an agent that may enhance mucociliary clearance.
  • Dry powder mannitol offers a potentially more convenient alternative to nebulized treatments.

Purpose of the Study:

  • Assess mannitol's tolerability, impact on quality of life, and respiratory function in CF patients.
  • Identify adverse events associated with inhaled dry powder mannitol therapy.

Main Methods:

  • Systematic review of randomized controlled trials comparing mannitol to placebo, active comparators, or no treatment.
  • Data extraction and risk of bias assessment by independent authors.
  • Quality of evidence assessed using GRADE methodology.

Main Results:

  • Moderate-quality evidence shows mannitol improves lung function (FEV1) over six months compared to control.
  • Low to very low-quality evidence indicates no consistent difference in quality of life.
  • Adverse events like cough and bronchospasm were reported but not significantly different between groups.

Conclusions:

  • Mannitol may be considered for CF treatment, with moderate evidence for lung function improvement.
  • Low-quality evidence suggests no significant difference when compared to dornase alfa.
  • Further research is needed to determine optimal patient selection, long-term efficacy, and comparative effectiveness against other mucolytics.